S.Biomedics Past Earnings Performance
Past criteria checks 0/6
S.Biomedics has been growing earnings at an average annual rate of 7.9%, while the Biotechs industry saw earnings growing at 14.4% annually. Revenues have been growing at an average rate of 26.9% per year.
Key information
7.9%
Earnings growth rate
28.0%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 26.9% |
| Return on equity | -56.8% |
| Net Margin | -57.9% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How S.Biomedics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 12,698 | -7,357 | 5,833 | 6,100 |
| 31 Dec 23 | 13,108 | -7,524 | 5,590 | 6,508 |
| 30 Sep 23 | 12,549 | -7,306 | 5,204 | 6,613 |
| 30 Jun 23 | 13,790 | -6,809 | 3,752 | 7,426 |
| 31 Mar 23 | 12,825 | -6,987 | 4,408 | 6,039 |
| 31 Dec 22 | 12,113 | -6,327 | 4,068 | 5,489 |
| 30 Sep 22 | 10,551 | -6,669 | 3,940 | 5,201 |
| 30 Jun 22 | 8,631 | -6,502 | 4,563 | 4,227 |
| 31 Mar 22 | 8,173 | -5,723 | 3,325 | 5,199 |
| 31 Dec 21 | 8,868 | -5,667 | 3,170 | 5,525 |
| 30 Sep 21 | 9,393 | -5,628 | 3,060 | 5,633 |
| 30 Jun 21 | 8,844 | -6,141 | 3,464 | 5,422 |
| 31 Mar 21 | 6,984 | -7,468 | 3,653 | 5,739 |
| 31 Dec 20 | 5,319 | -7,747 | 3,813 | 5,559 |
| 30 Sep 20 | 4,688 | -8,029 | 3,536 | 6,151 |
| 30 Jun 20 | 5,112 | -8,328 | 3,890 | 6,380 |
| 31 Mar 20 | 5,632 | -8,108 | 3,881 | 6,175 |
| 31 Dec 19 | 5,014 | -8,098 | 3,854 | 5,927 |
| 30 Sep 19 | 4,174 | -10,265 | 4,084 | 4,772 |
| 30 Jun 19 | 3,258 | -9,357 | 3,443 | 3,947 |
| 31 Mar 19 | 2,823 | -10,778 | 3,200 | 3,721 |
| 31 Dec 18 | 3,160 | -10,200 | 3,076 | 3,189 |
| 31 Dec 17 | 7,633 | -5,250 | 3,559 | 2,233 |
Quality Earnings: A304360 is currently unprofitable.
Growing Profit Margin: A304360 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A304360 is unprofitable, but has reduced losses over the past 5 years at a rate of 7.9% per year.
Accelerating Growth: Unable to compare A304360's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A304360 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (13.4%).
Return on Equity
High ROE: A304360 has a negative Return on Equity (-56.82%), as it is currently unprofitable.